Undecimal Bio
Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease.
$18MSeed
ParticipantSC
Saras Capital
Activity from announced rounds
Activity in this selectionEurope · Seed
Saras Capital is the investor linked by Biographica, Converge and Shennon sources to Nadav Rosenberg.
Recorded funding activity
Biographica develops crop traits using AI discovery. Converge supplies drug-discovery models, while Shennon develops cancer therapies. These company records preserve separate biological applications and financing events.
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $18M 1 disclosed · full round size, not this investor’s share